Structure of an anti-PD-1/HER2 bispecific antibody




FIG. 1

Trend of change in turbidity of anti-PD-1/HER2 bispecific antibody formulations at pH 5.0–6.5 ($OD_{350\,nm}$ method)




FIG. 2

Trend of change in protein purity of samples determined by SEC-HPLC (40±2 °C)




FIG. 3

Trend of change in protein purity of samples determined by non-reduced CE-SDS (40±2 °C)




FIG. 4

Trend of change in protein purity of samples determined by reduced CE-SDS (40±2 °C)




FIG. 5

Trend of change in charge variant-principal component of samples determined by iCIEF (40±2 °C)




FIG. 6

Anti-PD-1/HER2 bispecific antibody formulations comprising different stabilizers

Trend of change in charge variant-principal component over time determined by iCIEF (40 °C)




FIG. 7

Anti-PD-1/HER2 bispecific antibody formulations comprising different stabilizers

Trend of change in charge variant-principal component over time determined by iCIEF (25±2 °C)




FIG. 8